Patterson D, Kravtsova V M, Petrova E M, Zabelina T S, Balaian L N
Ter Arkh. 1987;59(12):81-6.
A total of 45 patients were given cytosar and daunorubicin therapy at small doses. Of them 23 patients were with acute nonlymphoblastic leukemia, 12--with hemopoietic dysplasia, and 10--with chronic myeloid leukemia. Cytosar was injected subcutaneously every 12 h at a dose of 10 mg/m2 for 10-25 days, daunorubicin was injected intravenously by drop infusion at a dose of 5 mg/m2. Clinicohematological remission was obtained in 13 patients, clinicohematological improvement in 16. Thus, a positive effect was achieved in 29 patients (64%). The authors provided some data on the influence of small doses of cytosar and daunorubicin on cell maturation in vitro.
共有45例患者接受了小剂量阿糖胞苷和柔红霉素治疗。其中23例为急性非淋巴细胞白血病患者，12例为造血发育异常患者，10例为慢性髓性白血病患者。阿糖胞苷每12小时皮下注射一次，剂量为10mg/m²，持续10 - 25天，柔红霉素以5mg/m²的剂量静脉滴注。13例患者获得临床血液学缓解，16例患者临床血液学改善。因此，29例患者（64%）取得了积极效果。作者提供了一些关于小剂量阿糖胞苷和柔红霉素对体外细胞成熟影响的数据。
